本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 陕西盘龙药业集团股份有限公司（以下简称"公司"）于 2025 年 9 月 19 日召开了第五届董事会第一次会议，分别审议通过了选举公司第五届董事会董事 长、各专门委员会委员、聘任高级管理人员及证券事务代表等相关议案。现将具 体情况公告如下： 一、第五届董事会董事长选举情况 经与会董事审议，同意选举谢晓林先生为公司第五届董事会董事长，任期三 年，自第五届董事会第一次会议审议通过之日起至第五届董事会任期届满之日止。 二、公司第五届董事会各专门委员会组成情况 第五届董事会专门委员会组成情况如下： 证券代码：002864 证券简称：盘龙药业 公告编号：2025-045 陕西盘龙药业集团股份有限公司 关于选举董事长、专门委员会委员、聘任高级管理人员及证券 事务代表的公告 | 序号 | 专门委员会名称 | 主任委员 | 委员 | | --- | --- | --- | --- | | 1 | 审计委员会 | 王鹏 | 王鹏、王满仓、朱文锋 | | 2 | 可持续战略发展委员会 | 谢晓林 | 谢晓林、张德柱、牛晓峰 | | ...

证券代码：002864 证券简称：盘龙药业 公告编号：2025-044 陕西盘龙药业集团股份有限公司 第五届董事会第一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 陕西盘龙药业集团股份有限公司（以下简称"公司"）第五届董事会第一次 会议通知于 2025 年 9 月 16 日以邮件方式向各位董事、独立董事发出。本次会议 于 2025 年 9 月 19 日下午 14:00 在西安市灞桥区现代纺织产业园灞柳二路 2801 号陕西盘龙医药股份有限公司二楼会议室采取现场结合通讯方式召开。会议应出 席董事 9 名，实际出席董事 9 名。经与会董事一致推选，本次会议由谢晓林先生 主持。公司全体高级管理人员候选人列席了本次会议。 会议的召集、召开和表决程序符合《中华人民共和国公司法》等法律、行政 法规、部门规章、规范性文件及《陕西盘龙药业集团股份有限公司章程》的有关 规定。 二、董事会会议审议情况 经与会董事认真审议，形成以下决议： 案》 董事会同意选举以下人员为第五届董事会各专门委员会委员，任期三年，自 本次董事会审议通过之日起至本 ...

中国资产评估协会 资产评估业务报告备案回执 | 报告编码: | 6161070005202500164 | | | --- | --- | --- | | 合同编号: | ZDXP-2025-175 | | | 报告类型: | 非法定评估业务资产评估报告 | | | 报告文号: | 陕正德信评报字(2025) 145号 | | | 报告名称: | 陕西盘龙药业集团股份有限公司拟购买资产所涉及的碧翠苑5号楼 项目资产评估报告 | | | 评估结论: | 67,791,500.00元 | | | 评估报告日: | 2025年09月12日 | | | 评估机构名称: | 陕西正德信资产评估有限公司 | | | 签名人员: | 郭凯 (资产评估师) | 正式会员 编号: 61200025 | | | 赵养峰 (资产评估师) | 正式会员 编号: 61200038 | | | 郭凯、赵养峰已实名认可 | | (可扫描二维码查询备案业务信息) 说明:报告备案回执仅证明此报告已在业务报备管理系统进行了备案,不作为 协会对该报告认证、认可的依据,也不作为资产评估机构及其签字资产评估专 业人员免除相关法律责任的依据。 备案回执 ...

Core Viewpoint - The company is actively expanding its traditional Chinese medicine (TCM) granule business, innovating drug development, optimizing dividend policies, and enhancing grassroots market strategies to drive growth and improve investor returns [1][2][3][4][5]. Group 1: TCM Granule Business - The TCM granule business is in its early stages but is steadily expanding, with the completion of an intelligent production line by the end of 2024 and the establishment of a business development center [2]. - As of now, the company has completed the research and registration of 310 products, with listings in 18 provinces, focusing on expanding from Shaanxi province [2]. Group 2: Innovative Drug Development - The company is making progress in innovative drug development, with the modified TCM new drug PL JT004 entering the CDE clinical acceptance stage, and the chemical generic drug PL-JT001 completing bioequivalence testing [3]. - Additional chemical generics (PLJT - 002/003) are set to initiate IND applications within the year, while 1.1 class innovative TCM drugs are advancing through preclinical and phase II work [3]. - The company aims to cultivate major products through a tiered pipeline layout, enhancing product competitiveness [3]. Group 3: Dividend Policy - The company emphasizes investor returns and has approved a three-year dividend return plan for 2025-2027, balancing current shareholder returns with long-term development through management innovation and profit quality improvement [4]. Group 4: Grassroots Market Development Strategy - The company is focusing on grassroots market development while maintaining high coverage in tiered hospitals, employing a multi-faceted marketing model that integrates products, academia, terminals, and branding [5]. - Currently, the products cover over 20,000 grassroots medical institutions and more than 30,000 retail pharmacies, establishing a dual-driven model of medical and retail [5].

Group 1: Business Development and Growth Strategies - The company has completed the construction of an intelligent production line for traditional Chinese medicine formula granules by the end of 2024, with 310 varieties registered and listed in 18 provinces [2][3] - The company is focusing on expanding its traditional Chinese medicine formula granules business, starting from Shaanxi province and gradually extending its coverage [2][3] - The company is advancing its innovative drug development strategy, with several products in various stages of clinical trials and regulatory submissions [3][4] Group 2: Financial Performance and Shareholder Returns - The company emphasizes enhancing shareholder returns through increased dividend ratios and frequency, with a three-year dividend return plan approved for 2025-2027 [3][4] - The management is committed to balancing short-term shareholder returns with long-term company growth, focusing on management innovation and optimizing cost structures to support dividends [3][4] Group 3: Market Expansion and Marketing Strategies - The company has established a comprehensive marketing management system to expand its presence in grassroots markets while maintaining high coverage in tiered hospitals [4][5] - The product distribution has reached over 20,000 grassroots medical institutions and more than 30,000 retail pharmacies, creating a dual-driven model of medical and retail [4][5] - The company is actively developing an "Internet + Medicine" strategy, forming a professional digital marketing team and collaborating with leading e-commerce platforms [5]

Core Viewpoint - The Chinese medicine sector is experiencing a mixed performance, with the leading Chinese medicine ETF (560080) showing resilience despite market fluctuations, attracting significant capital inflows and demonstrating strong growth potential in the context of regulatory changes and industry innovation efforts [1][4][6]. Market Performance - The Chinese medicine ETF (560080) recorded a slight decline but maintained a premium throughout the day, with a trading volume exceeding 71 million yuan. Over the past 10 days, it has seen net inflows on 9 occasions, totaling over 150 million yuan, and its latest scale has surpassed 2.4 billion yuan, leading its peers [1][4]. - Major components of the ETF index mostly experienced pullbacks, with Renhe Pharmaceutical declining over 1%, while Panlong Pharmaceutical rose over 1% [3][5]. Financing and Investment Trends - Leveraged funds are increasingly utilizing the ETF to invest in the high-value Chinese medicine consumer sector, with the latest financing balance approaching 80 million yuan and a financing buy-in amount exceeding 12 million yuan as of September 16, 2025 [4]. - The Chinese medicine industry is viewed as having stable cash flow and high dividends, with companies like Huaren Sanjiu and Jiangzhong Pharmaceutical showing strong performance in their incentive plans, which are expected to drive new growth [7][8]. Regulatory Developments - The National Medical Products Administration has announced new regulations for Chinese medicine production supervision, effective March 1, 2026, emphasizing quality control throughout the entire production process [5]. Innovation and Growth Strategies - Chinese medicine companies are actively pursuing innovation and transformation into chemical and biological pharmaceuticals through self-research, mergers and acquisitions, and strategic partnerships, aiming to create a second growth curve [6]. - The industry is expected to see improved performance in the second half of 2025, driven by reduced cost pressures from declining raw material prices and enhanced operational efficiencies [7][9]. Dividend and Profitability Insights - A significant number of central state-owned enterprises in the Chinese medicine sector are projected to have dividend yields exceeding 3% in 2024, with Jiangzhong Pharmaceutical and Dong'e Ejiao leading in dividend rates [8][9]. - Despite facing growth pressures in the first half of 2025, many companies have managed to achieve positive growth in net profit through quality improvement and efficiency enhancement strategies [9]. Market Sentiment and Future Outlook - The Chinese medicine index is gradually recovering, with institutional holdings remaining light. The sector is expected to attract more capital as it combines attributes of new consumer demand and pharmaceutical needs [10][12].

Group 1 - The core viewpoint of the news is that Panlong Pharmaceutical experienced a stock price increase of 5.06%, reaching 32.79 CNY per share, with a total market capitalization of 3.485 billion CNY [1] - Panlong Pharmaceutical, established on September 22, 1997, is located in Xi'an, Shaanxi Province, and was listed on November 16, 2017. The company specializes in the research, production, and sales of traditional Chinese medicine [1] - The main business revenue composition of Panlong Pharmaceutical includes 55.50% from self-produced traditional Chinese medicine, 22.42% from pharmaceutical distribution, 21.42% from traditional Chinese medicine pieces, and 0.52% from other sources [1] Group 2 - Among the top circulating shareholders of Panlong Pharmaceutical, a fund under Huatai PineBridge has reduced its holdings by 36,500 shares, now holding 342,500 shares, which accounts for 0.46% of the circulating shares [2] - The Huatai Zhongzheng Traditional Chinese Medicine ETF (560080) was established on September 26, 2022, with a current scale of 1.814 billion CNY. It has achieved a return of 1.14% this year, ranking 4129 out of 4222 in its category [2] - The fund has a one-year return of 20.45%, ranking 3665 out of 3804, and a cumulative return of 10.4% since its inception [2]

Core Points - On September 15, the company announced that it held a staff representative meeting on September 12, 2025, where Zhu Wenfeng was democratically elected as the employee representative director of the fifth board of directors [2]

陕西盘龙药业集团股份有限公司（以下简称"公司"）第四届董事会任期即 将届满，根据《中华人民共和国公司法》《深圳证券交易所股票上市规则》《深 圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等规范 性文件及《公司章程》的有关规定，为保证董事会的正常运行，公司于 2025 年 9 月 12 日在公司会议室召开职工代表大会，经与会职工代表民主选举，同意朱 文锋先生为公司第五届董事会职工代表董事，朱文锋先生的简历详见附件。 朱文锋先生符合相关法律法规、有关董事任职的资格和条件，将与 2025 年 第二次临时股东会选举产生的非独立董事和独立董事共同组成公司第五届董事 会，任期自本次职工代表大会审议通过之日起至第五届董事会任期届满之日止。 本次选举职工代表董事工作完成后，公司董事会中兼任高级管理人员以及由职工 代表担任的董事人数，总计未超过公司董事总数的二分之一。 关于选举第五届董事会职工代表董事的公告 特此公告。 陕西盘龙药业集团股份有限公司董事会 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：002864 证券简称：盘龙药业 公告编号： ...

证券代码：002864 证券简称：盘龙药业 公告编号：2025-043 陕西盘龙药业集团股份有限公司 关于董事会完成换届选举的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 非独立董事：谢晓林先生、谢晓锋先生、张德柱先生、吴杰先生、黄继林先 生、朱文锋先生（职工代表董事）； 公司第五届董事会成员均具备担任上市公司董事的任职资格，任期自公司 2025 年第二次临时股东会审议通过之日起三年。董事会中兼任公司高级管理人 员以及由职工代表担任的董事人数总计未超过公司董事总数的二分之一，符合 《中华人民共和国公司法》和《公司章程》的有关规定。独立董事的任职资格和 独立性已经深圳证券交易所备案审核无异议。 陕西盘龙药业集团股份有限公司（以下简称"公司"）于 2025 年 9 月 12 日召开了职工代表大会，选举产生了 1 名职工代表董事，并于 2025 年 9 月 15 召开了 2025 年第二次临时股东会，选举产生了 5 名非独立董事和 3 名独立董事， 共同组成了公司第五届董事会。现将具体情况公告如下： 一、公司第五届董事会组成情况 公司第五届董事会成员为 9 ...